Non-ergot dopamine D2/D3 receptor agonist
ATC code: N04BC05 (Pramipexole)
A selective D2-family dopamine receptor agonist with preferential D3 affinity (5–7-fold over D2). Mimics dopamine action in nigrostriatal and mesolimbic pathways. Compared with ergot agonists (bromocriptine, pergolide), no risk of fibrotic complications (valvular heart disease, pulmonary fibrosis). Half-life 8–12 hours immediate-release; 22 hours extended-release.
First line
First-line in Parkinson's disease in patients under 65 to delay levodopa per 2021 and SEN 2024. In patients over 65, levodopa start is preferred. Starting dose 0.125 mg three times daily (immediate-release) or 0.375 mg once daily (extended-release), slowly titrated to 1.5–4.5 mg daily. Added to levodopa for motor fluctuations. CALM-PD showed pramipexole reduces dyskinesia risk by 50% in the first 5 years but causes more non-motor side effects.
Second line
Second-line for moderate-to-severe restless legs syndrome per 2024 and EFNS/ENS 2012. First-line is iron supplementation in ferritin deficiency (under 75 ng/mL) and α2δ ligands (gabapentin, pregabalin). Pramipexole 0.125–0.5 mg 2–3 hours before bed. Long-term use is linked to augmentation phenomenon – symptom worsening with daytime spread; when augmentation appears, switch the drug.
The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.
Not recommended
Pramipexole is a dopamine receptor agonist. It is prescribed for Parkinson's disease and for moderate-to-severe restless legs syndrome (RLS) ( 2018 guidelines and AEMPS Ficha Técnica). For unconfirmed mild RLS or stress-related muscle tension, pramipexole is not used: these indications are not in international guidelines. The drug has serious risks: pathological gambling, hypersexuality, compulsive eating and shopping ( warning, 2014), sudden sleep attacks with risk of falling asleep at the wheel, and augmentation on long-term RLS treatment (paradoxical worsening of symptoms). If pramipexole was prescribed for leg sensations or muscle relaxation outside confirmed RLS, consider seeking a second opinion and check serum ferritin (iron deficiency is a common cause of RLS).
Opens the checker prefilled with this drug. Pick the second one from your regimen.
Direct links to regulator labels. Open in a new tab.
Limited data. In pregnant Parkinson's patients, decisions are made with the neurologist.
Suppresses lactation via prolactin inhibition. Not used during lactation.
Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.
Pramipexole is evaluated for the following indications with varying evidence strength: Restless legs syndrome (evidence tier A), Parkinson's disease (evidence tier A), Insomnia and sleep disorders (evidence tier F). See the full indication matrix with dosing and citations above on this page.
Common side effects of Pramipexole (≥ 1 in 100): Nausea, Drowsiness and sudden sleep attacks, Dizziness, Orthostatic hypotension, Dyskinesias (in Parkinson's with concomitant levodopa), Constipation. See the Safety section for uncommon and serious reactions.
FDA category C. Limited data. In pregnant Parkinson's patients, decisions are made with the neurologist.
Suppresses lactation via prolactin inhibition. Not used during lactation.
Pramipexole is contraindicated in: Pramipexole hypersensitivity; Severe renal impairment without dose adjustment; Pregnancy and lactation; Age under 18. Full list in the Safety section.